Three F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug

www.nytimes.com
3 min read
fairly difficult
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.
The F.D.A.'s decision to green-light it, announced Monday, marked the first approval of an Alzheimer's treatment in 18 years. Patient advocacy groups had pushed for approval because there are only five other medications available for the debilitating condition and they only address dementia symptoms for a matter of months.

But since at least last fall, several respected experts, including some Alzheimer's doctors who worked on the aducanumab clinical trials, have said the available evidence raised significant doubts about whether the drug is effective. They also said that even if it could slow cognitive decline in some patients, the suggested benefit — a slowing of symptoms for roughly four…
Pam Belluck, Rebecca Robbins
Read full article